New ACIP Panel Votes to Recommend Clesrovimab, Second Antibody to Prevent RSV in Infants

The seven newly appointed members of ACIP voted 5-to-2 to recommend Enflonsia, the second long-acting monoclonal ...

JUNE 26, 2025

FDA Requires GBS Warning for RSV Vaccines

The FDA required and approved safety labeling changes to the prescribing information for RSV vaccines to include a ...

JANUARY 14, 2025

RSV Vaccine Safety Findings Similar to Clinical Trial Results

GSB continues to be the most common serious adverse event from RSV vaccinations, but the effect is relatively rare. ...

JULY 18, 2024

ACIP Updates RSV Vaccine Recommendations

After receiving real-world data, ACIP updated its recommendations about shared decision making and other issues ...

JUNE 27, 2024

FDA Grants Expanded Indication for GSK’s Arexvy

The FDA granted a new indication for GSK’s Arexvy adjuvanted respiratory syncytial virus vaccine to prevent ...

JUNE 13, 2024

CDC Addresses RSV Vaccine Administration Errors

Potentially dangerous administration errors for RSV vaccines are occurring in young children and pregnant people, ...

APRIL 21, 2024

Preventive Therapies for Respiratory Syncytial Virus

RSV is a prevalent pathogen that presents as a minor common cold in most individuals, but poses a higher risk to ...

FEBRUARY 13, 2024

Vaccination Against U.S. Respiratory Diseases Remains Low

Vaccination against COVID-19, influenza and RSV remains low in the United States, and is particularly low for ...

FEBRUARY 2, 2024